A Smart + Strong Site
Subscribe to:
E-newsletters
POZ magazine
JOIN AIDSMEDS YouTube

Back to home » Treatment News » Top Stories

Most Popular Stories
Undetectable Viral Load Essentially Eliminates Transmission Risk in Straight Couples
A 15-Year Jump in Life Expectancy for People With HIV
Life Expectancy for Young People With HIV Is Nearly Normal
Failure to Awaken Dormant Cells Deals Blow to HIV Cure Research
Scientists Devise Method of Snipping HIV From Immune Cells
Media Cooks Up Claim That Soy Sauce Treats, Even Cures HIV
FDA Approves New Single-Tablet HIV Regimen, Triumeq
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

Most Popular Lessons
Aging & HIV
The HIV Life Cycle
Shingles
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to news@aidsmeds.com.

Click here for more news


emailprint

March 28, 2014

PrEP Adherence Varies Greatly Between Cities

Adherence to the daily regimen of Truvada (tenofovir/emtricitabine) as pre-exposure prophylaxis (PrEP) against HIV infection varied widely in studies conducted in three different cities. Findings from the study were presented at the Conference on Retroviruses and Opportunistic Infections (CROI) in Boston and reported by aidsmap.

A total of 1,059 gay or bisexual men or transgender women visiting sexual health clinics in San Francisco, Miami and Washington, DC, were offered the chance to be screened for eligibility to participate in an open-label trial of Truvada as PrEP.

Those who sought out the study of their own accord, as opposed to being referred by a doctor, were more likely to be white, have a higher level of education and to be both at high risk of HIV acquisition and to see themselves as at high risk.

The approximately 600 men and trans women who ultimately participated were 32 years old on average. Forty-eight percent of the cohort was white, 35 percent Latino and just 8 percent black.

The study investigators randomly selected about a third of the men to receive drug-level testing to determine their adherence to Truvada. Fifty-two percent of those in San Francisco had levels of the drug in their blood that indicated they were taking the drug daily as prescribed, compared with 35 percent of those in Washington and just 13.5 percent in Miami.

Forty-three percent of the participants in both Miami and Washington and 40 percent of those in San Francisco were apparently taking Truvada about four days a week, which research has suggested reduces the likelihood of HIV transmission by about 96 percent. Thus, 92 percent of the participants in San Francisco, 57 percent of those in Washington and 57 percent of those in Miami were probably protected against HIV acquisition by at least that factor.

The respective percentages of those taking two doses a week, which confers about 70 percent protection, were: 27 percent among Miamians and 4 percent among both Washingtonians and San Franciscans. The respective proportions that took one dose a week, which offers very little protection against HIV, were 11 percent, 2 percent and 4 percent. And finally, a respective 4.5 percent, 2 percent and zero did not have detectable levels of Truvada.

To read the aidsmap story, click here.

Search: Truvada, PrEP, pre-exposure prophylaxis, HIV, tenofovir, emtricitabine, aidsmap, Conference on Retroviruses and Opportunistic Infections, CROI.


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team reviews all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)


[Go to top]

Quick Links
AIDSmeds en Español
About HIV and AIDS
Lab Tests
Clinical Trials
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Disclosure
Lipodystrophy
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Blogs
Conference Coverage
Health Services Directory
POZ Magazine


    dlw8585
    Fort Lauderdale
    Florida


    july8th69
    brooklyn
    New York


    youngbloodlatino
    Columbia
    Maryland


    HOTROD2010
    houston
    Texas
Click here to join POZ Personals!
Conference Coverage

XX International AIDS Conference
(AIDS 2014)
Melbourne, Australia
July 20 - 25, 2014


21st Conference on Retroviruses and Opportunistic Infections
(CROI 2014)
Boston, MA
March 3 - 7, 2014


7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention
(IAS 2013)
Kuala Lumpur, Malaysia
June 30 - July 3, 2013


more conference coverage

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.